134 related articles for article (PubMed ID: 33838962)
1. Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.
Roumiguie M; Contreras-Sanz A; Black PC
Eur Urol; 2021 Jun; 79(6):e182-e183. PubMed ID: 33838962
[No Abstract] [Full Text] [Related]
2. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
4. Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
Yang A; Cannataro VL; Townsend JP
Eur Urol; 2020 Jan; 77(1):e24-e25. PubMed ID: 31474441
[No Abstract] [Full Text] [Related]
5. Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
Massari F; Di Nunno V
Eur Urol; 2018 Jul; 74(1):e12-e13. PubMed ID: 29656855
[No Abstract] [Full Text] [Related]
6. Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2021 May; 79(5):e158-e159. PubMed ID: 33579575
[No Abstract] [Full Text] [Related]
7. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
8. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
10. Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
Perez-Gracia JL
Eur Urol; 2018 Jul; 74(1):e14. PubMed ID: 29656856
[No Abstract] [Full Text] [Related]
11. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
Palma N; Morris JC; Ali SM; Ross JS; Pal SK
Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722
[No Abstract] [Full Text] [Related]
12. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13.
Shi MJ; Meng XY; Chen CL; Dyrskjøt L; Radvanyi F; Prokunina-Olsson L; Bernard-Pierrot I
Eur Urol; 2020 Jan; 77(1):e26-e27. PubMed ID: 31493961
[No Abstract] [Full Text] [Related]
13. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
15. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
[TBL] [Abstract][Full Text] [Related]
17. Re: Analysis of Papillary Urothelial Carcinomas of the Bladder with Grade Heterogeneity: Supportive Evidence for an Early Role of CDKN2A Deletions in the FGFR3 Pathway.
Varinot J; Compérat E
Eur Urol; 2017 Apr; 71(4):690. PubMed ID: 28117111
[No Abstract] [Full Text] [Related]
18. Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Montironi R; Lopez-Beltran A; Cheng L
Eur Urol; 2008 Oct; 54(4):843-4. PubMed ID: 18166261
[No Abstract] [Full Text] [Related]
19. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
20. The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma.
Keck B; Stoehr R; Wach S; Rogler A; Hofstaedter F; Lehmann J; Montironi R; Sibonye M; Fritsche HM; Lopez-Beltran A; Epstein JI; Wullich B; Hartmann A
Int J Cancer; 2011 Jul; 129(2):346-54. PubMed ID: 20878954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
